Does the name mean BPC-157 protects the body?

No. It records a hypothesis the Zagreb group formed at discovery. Names of that kind assert a function rather than describe a demonstrated one.

Is the hypothesis being tested?

Yes. NCT07437547 is a randomised, double-blind, placebo-controlled Phase 2 trial with primary completion due February 2027.

How does this compare to DSIP?

Both are named for a proposed function. DSIP has no gene, no receptor and no clinical programme; BPC-157 has a large preclinical literature and registered trials.

Why It Is Called Body Protection Compound

The short answer

The Zagreb group named the gastric juice protein body protection compound to reflect a hypothesised protective role. The name records a hypothesis from the time of discovery rather than a demonstrated function, and it has carried an implicit claim ever since.

Key facts

Named by: The Zagreb research group
Refers to: A protein in human gastric juice
BPC-157: A 15-residue partial sequence of it
The name asserts: A protective function
Status of that claim: Preclinical; one Phase 2 recruiting
Comparable case: Delta sleep-inducing peptide

The reasoning behind the name

Gastric juice is a hostile environment (strongly acidic and rich in proteases), and the stomach lining survives it. That observation invites the hypothesis that something in gastric juice is protective, and a protein isolated from it that appeared to have protective effects in lesion models was named accordingly.

What a functional name does to a reader

It supplies a conclusion before any evidence is examined. Body protection compound sounds like a description; it is a proposal. The same is true of delta sleep-inducing peptide, and of liver cell growth factor, GHK's original name. All three were named for what an investigator believed they had found. Two of those names did not survive scrutiny.

Research material referenced

BPC-157 5mg, third-party HPLC tested

Buy BPC-157 · £15.99

How BPC-157 differs from those cases

It has more behind it. DSIP has no gene, no receptor and an unresolved central claim. GHK's early name was abandoned once its actual chemistry became clear. BPC-157 has a large preclinical literature across multiple model systems, earlier clinical development as PL-14736, and a randomised placebo-controlled Phase 2 recruiting now. The name is still a hypothesis, but the hypothesis is being tested properly.

What would settle it

NCT07437547: a randomised, double-blind, placebo-controlled Phase 2 trial in 120 participants with acute hamstring strain, sponsored by a party unconnected to the original research group, with primary completion due 14 February 2027. That design is what converts a hypothesis into a result, whichever direction it goes.

The position until then

The name is not evidence. The preclinical literature is substantial but concentrated in one group. The clinical evidence is a completed Phase 1 and a Phase 2 that has not reported. That is an interesting position for a research compound to be in, and it is not the same as a demonstrated protective effect in anyone.

Frequently asked questions

Does the name mean BPC-157 protects the body?: No. It records a hypothesis the Zagreb group formed at discovery. Names of that kind assert a function rather than describe a demonstrated one.
Is the hypothesis being tested?: Yes. NCT07437547 is a randomised, double-blind, placebo-controlled Phase 2 trial with primary completion due February 2027.
How does this compare to DSIP?: Both are named for a proposed function. DSIP has no gene, no receptor and no clinical programme; BPC-157 has a large preclinical literature and registered trials.

Extended research context

The BPC-157 (Pentadecapeptide) deep dive

Deep dive: the pentadecapeptide sequence

BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a fragment identified in human gastric juice by the Zagreb research group (Sikirić and colleagues), whose body of published work spans three decades and covers models ranging from tendon repair to gut integrity. The 'BPC' initials stand for 'body protection compound', the group's original characterisation term.

Two forms: acetate salt vs arginate

BPC-157 is supplied most commonly as an acetate salt; a small subset of suppliers offer the arginate form, which has slightly different solubility and stability properties. For research reproducibility, keep the salt form consistent across a study and confirm which form the CoA specifies (mass ± counterion changes the reading).

Reading a BPC-157 CoA

A trustworthy BPC-157 CoA lists HPLC purity (target ≥98% area), mass-spec confirmation (~1,419 Da for the free peptide), water content (Karl Fischer), acetate content, and residual solvents. Some batches also include endotoxin data. Any missing category is a red flag for a compromised supply chain.

Research applications

▸Cell-culture models of gut epithelial integrity
▸Tendon fibroblast migration and collagen-synthesis assays
▸Angiogenesis models involving VEGF and NO signalling
▸Stability studies comparing acetate vs arginate salt forms
▸Analytical reference for pentadecapeptide HPLC methods

Handling checklist

✓Store lyophilised vial at −20 °C long-term (2–8 °C short-term)
✓Reconstitute with bacteriostatic water; a 5 mg vial dissolves cleanly
✓Aliquot reconstituted solution; keep refrigerated 2–8 °C, use within 28 days
✓Protect from light and repeated warming
✓Verify CoA: HPLC ≥98%, mass ~1,419 Da, salt form declared

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Mixing acetate and arginate BPC-157 across a study

Fix: Choose one salt form and stay with it. Different masses and solubility.

✗ Assuming stability at room temperature

Fix: Refrigerate reconstituted solution; discard after 28 days.

✗ Buying without a CoA

Fix: Only source from suppliers that publish batch HPLC + mass-spec data.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More BPC-157 (Pentadecapeptide) articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

Body Protection Compound: A Name That Is a Hypothesis